Raynaud's Drugs: Medications That Cause or Treat It

What Is Raynaud's Phenomenon and Why Do Drugs Matter?

Raynaud's phenomenon is episodic vasospasm of the digital arteries and arterioles, typically triggered by cold exposure or emotional stress, producing the classic white-blue-red color sequence in fingers or toes. It affects an estimated 3 to 5% of adults worldwide [1]. Drug-induced Raynaud's is an underrecognized contributor.

The distinction between primary and secondary Raynaud's determines clinical urgency. Primary Raynaud's (previously called Raynaud's disease) occurs without an underlying autoimmune or vascular condition and represents about 80% of cases [1]. Secondary Raynaud's is associated with connective tissue diseases, most notably systemic sclerosis (SSc), where prevalence reaches 90 to 95% [2]. Medications enter the picture on both sides of this equation. Some drugs provoke vasospasm and create or worsen Raynaud's episodes. Others relax vascular smooth muscle or modulate endothelial function to reduce attack severity and frequency.

The 2022 American College of Rheumatology (ACR) guidelines on systemic sclerosis-associated Raynaud's conditionally recommend dihydropyridine calcium channel blockers as first-line pharmacotherapy [3]. Understanding which medications sit on which side of the ledger is relevant for any patient experiencing episodic digital ischemia. A medication review should be one of the first steps in evaluation.

Drugs That Cause or Worsen Raynaud's

Beta-blockers, ergot alkaloids, and several chemotherapy agents are the most established pharmacologic triggers of Raynaud's phenomenon. Stopping or substituting the offending drug often resolves symptoms entirely [4].

Beta-adrenergic blockers are the most frequently implicated class. Non-selective agents like propranolol carry higher risk than cardioselective agents like metoprolol, though even selective beta-blockers can trigger episodes in susceptible individuals [4]. The mechanism involves blocking beta-2-mediated vasodilation in peripheral arteries, leaving alpha-adrenergic vasoconstriction unopposed. A 2019 BMJ Best Practice review noted that "beta-blockers should be avoided in patients with Raynaud's phenomenon whenever clinically feasible" [5].

Ergotamine and dihydroergotamine, once widely prescribed for migraine, cause direct arterial vasoconstriction and are well-documented triggers. Their use has declined sharply with the advent of triptans, though triptans themselves (particularly sumatriptan) have occasional vasospastic reports [6].

Chemotherapy agents represent a distinct risk category. Bleomycin, vinblastine, and cisplatin are the classic offenders, with Raynaud's developing in up to 37% of patients receiving bleomycin-containing regimens for testicular germ cell tumors [7]. The mechanism may involve direct endothelial toxicity rather than reversible vasospasm, meaning symptoms can persist after treatment ends.

Other implicated medications include:

• Stimulants (amphetamine, methylphenidate) through sympathomimetic vasoconstriction
• Cyclosporine, particularly at higher trough levels
• Interferons (interferon-alpha and interferon-beta)
• Clonidine, which can paradoxically trigger peripheral vasospasm despite being a centrally acting antihypertensive
• Bromocriptine and certain dopamine agonists
• Polyvinyl chloride exposure (occupational, not strictly a drug, but frequently grouped with chemical causes)

When Raynaud's symptoms appear after starting any new medication, the temporal relationship should prompt a trial discontinuation or substitution before adding vasodilator therapy [4].

First-Line Treatment: Calcium Channel Blockers

Dihydropyridine calcium channel blockers (CCBs) are the best-studied and most widely recommended first-line pharmacotherapy for Raynaud's phenomenon. Nifedipine leads the evidence base [3].

A Cochrane systematic review of 29 trials (N=1,596) found that CCBs reduced the frequency of Raynaud's attacks by a mean of 2.8 to 5 episodes per two weeks and decreased attack severity by approximately 33% compared with placebo [8]. Nifedipine extended-release (30 to 60 mg daily) is the most commonly used formulation. The typical starting dose is 30 mg once daily, titrated based on blood pressure tolerance and symptom response.

Amlodipine (5 to 10 mg daily) is a reasonable alternative with a longer half-life and potentially fewer reflex tachycardia episodes. A small randomized crossover trial (N=42) comparing amlodipine 10 mg to nifedipine retard 40 mg found similar reductions in attack frequency, with amlodipine showing marginally better tolerability [9].

The 2022 ACR/EULAR guidelines for SSc conditionally recommend dihydropyridine CCBs and state: "Nifedipine is the most studied calcium channel blocker for Raynaud's phenomenon and should be considered first-line in patients requiring pharmacotherapy" [3].

Side effects include headache (reported in 20 to 30% of patients), peripheral edema, dizziness, and flushing. These are dose-dependent and often improve after the first two weeks. Non-dihydropyridine CCBs such as diltiazem have less peripheral vasodilatory potency but are sometimes used when dihydropyridines are not tolerated, though evidence is weaker [8].

PDE5 Inhibitors for Refractory Raynaud's

When calcium channel blockers provide insufficient relief, phosphodiesterase type 5 (PDE5) inhibitors offer a second-tier option with growing evidence, particularly for secondary Raynaud's with digital ulceration [10].

Sildenafil has the most data. A meta-analysis of six RCTs (N=244) published in the Journal of Rheumatology found that PDE5 inhibitors reduced daily Raynaud's attack frequency by 0.49 attacks per day and decreased attack duration by 14.62 minutes compared with placebo [10]. Effect sizes were more pronounced in secondary Raynaud's associated with systemic sclerosis.

Dosing for Raynaud's is typically sildenafil 20 mg three times daily, though some clinicians titrate to 50 mg three times daily in severe cases. Tadalafil 20 mg every other day has also been studied, with its longer half-life (17.5 hours) offering practical advantages for adherence [10].

The mechanism involves inhibiting PDE5-mediated breakdown of cyclic GMP in vascular smooth muscle, promoting nitric oxide-dependent vasodilation. This pathway is distinct from the CCB mechanism of blocking L-type calcium channels, which is why combination therapy can be additive.

Dr. Fredrick Wigley, a rheumatologist at Johns Hopkins who has published extensively on Raynaud's, has noted that "PDE5 inhibitors represent the most important therapeutic advance for severe Raynaud's in the last two decades, particularly for patients with scleroderma-associated digital ischemia" [11].

Side effects include headache, flushing, dyspepsia, and nasal congestion. PDE5 inhibitors are contraindicated with concurrent nitrate use due to risk of severe hypotension.

Prostacyclin Analogues and Iloprost Infusion

Intravenous iloprost is the standard rescue therapy for severe Raynaud's with active digital ulcers or critical ischemia, particularly in systemic sclerosis [3].

The evidence base for iloprost rests on several European RCTs conducted in the 1990s and 2000s. A key multicenter trial (N=131) demonstrated that five consecutive daily infusions of iloprost (0.5 to 2 ng/kg/min over 6 hours) significantly reduced Raynaud's attack frequency and healed existing digital ulcers in 42.7% of patients versus 26.3% with placebo [12]. The treatment effect persisted for 6 to 9 weeks after infusion.

The 2022 ACR guidelines conditionally recommend IV iloprost for SSc-associated Raynaud's refractory to oral therapies [3]. In clinical practice, infusion cycles are typically repeated every 6 to 8 weeks during winter months.

Oral iloprost and oral treprostinil have been studied but show inconsistent results and significant gastrointestinal side effects. Epoprostenol (IV prostacyclin) is occasionally used in centers without iloprost access, though it requires continuous infusion and is less practical.

The side effect profile of IV iloprost includes headache, jaw pain, flushing, nausea, and hypotension during infusion. These effects are dose-dependent and managed by slowing the infusion rate. Iloprost is not FDA-approved for Raynaud's in the United States (it is approved for pulmonary arterial hypertension), so its use in digital ischemia is off-label, though well-supported by European guidelines and clinical practice [12].

Bosentan and Endothelin Receptor Antagonists

Bosentan holds a unique position as the only FDA-approved medication specifically indicated for reducing new digital ulcers in systemic sclerosis, though it does not improve Raynaud's attack frequency directly [13].

The RAPIDS-2 trial (N=188) demonstrated that bosentan 125 mg twice daily reduced the number of new digital ulcers by 30% compared with placebo over 24 weeks in SSc patients [13]. The drug did not significantly improve healing of existing ulcers, establishing its role as preventive rather than therapeutic for active ischemia.

Bosentan works by blocking endothelin-1 receptors (ETA and ETB), countering the potent vasoconstriction and vascular remodeling driven by endothelin-1, which is markedly elevated in systemic sclerosis [13]. Liver function monitoring is required due to dose-dependent hepatotoxicity (elevated transaminases occur in roughly 11% of patients). Monthly liver function tests are mandatory during treatment.

Macitentan, a newer dual endothelin receptor antagonist with a better hepatic safety profile, was studied in the DUAL-1 and DUAL-2 trials for SSc digital ulcers but failed to meet its primary endpoint [14]. As a result, bosentan remains the only endothelin receptor antagonist with a positive indication in this space.

Other Vasodilators and Adjunctive Therapies

Several additional drug classes show varying levels of evidence for Raynaud's management and may be considered in specific clinical scenarios [15].

Topical nitroglycerin applied to affected digits provides local vasodilation. A formulation (MQX-503) showed statistically significant improvements in blood flow in a phase II trial, though the clinical effect was modest and skin irritation was common [15]. Standard nitroglycerin ointment (2%) applied to the dorsum of affected fingers 15 minutes before cold exposure is used empirically, though headache limits adherence.

Prazosin (alpha-1 adrenergic blocker) at doses of 1 to 5 mg twice daily showed modest benefit in older RCTs, reducing attack frequency by roughly 1 to 2 episodes per week [16]. First-dose hypotension and dizziness are the main concerns. The evidence is considered low quality by current systematic reviews.

Fluoxetine (20 mg daily) was compared with nifedipine (40 mg daily) in a small crossover trial (N=27) and showed comparable reductions in attack severity, possibly through serotonin-mediated vascular effects [17]. This may be a useful dual-purpose option in patients with concurrent depression or anxiety.

Losartan (50 mg daily) reduced attack severity and frequency in a 15-week crossover RCT (N=25) compared with placebo, potentially through angiotensin II type 1 receptor blockade and downstream effects on nitric oxide bioavailability [18]. Its tolerability profile makes it attractive for patients who also need antihypertensive therapy.

Botulinum toxin A injection around digital arteries is an emerging approach. A retrospective series of 19 SSc patients showed improvement in pain scores and perfusion in 84% of treated hands, with effects lasting 2 to 3 months [19]. Prospective controlled trials remain limited.

When to Start Pharmacotherapy and How to Escalate

Not every Raynaud's patient needs medication. Behavioral measures (cold avoidance, insulated gloves, smoking cessation, stress management) should be tried first, particularly in primary Raynaud's [1].

The trigger for starting drug therapy is persistent, frequent attacks that impair daily function despite lifestyle modifications, or any evidence of digital ischemia (prolonged pallor, cyanosis lasting more than 20 minutes, digital pitting, or ulceration) [3]. All patients should have a medication review to identify and discontinue any drug-induced contributors before adding vasodilator therapy.

A practical escalation ladder based on current guidelines and expert consensus:

1. Step 1: Nifedipine extended-release 30 mg daily (titrate to 60 to 90 mg as tolerated)
2. Step 2: Add or switch to a PDE5 inhibitor (sildenafil 20 mg TID)
3. Step 3: IV iloprost infusion for refractory cases or active digital ulcers
4. Step 4: Consider bosentan for prevention of new digital ulcers in SSc
5. Step 5: Adjuncts (topical nitrates, prazosin, fluoxetine) as individual clinical scenarios dictate

Combination therapy is common in secondary Raynaud's. A CCB plus a PDE5 inhibitor is the most frequently used pairing in clinical practice. Monitoring blood pressure is necessary when combining vasodilators, as additive hypotension can occur [3].

Diagnosis and When to Seek Evaluation

Raynaud's is diagnosed clinically based on the characteristic triphasic color change (white, blue, red) in response to cold or stress. No single lab test confirms the diagnosis [1].

The distinction between primary and secondary Raynaud's drives the workup. Nailfold capillaroscopy is the single most useful test for identifying early secondary Raynaud's; abnormal capillary patterns (giant capillaries, hemorrhages, avascular areas) predict progression to systemic sclerosis with 47% sensitivity and 95% specificity [20]. Antinuclear antibody (ANA) testing, anti-centromere antibodies, and anti-Scl-70 (topoisomerase I) antibodies help classify autoimmune associations.

Red flags that warrant prompt rheumatology or vascular referral include: onset after age 30, asymmetric involvement, digital ulceration or gangrene, abnormal nailfold capillaroscopy, positive autoimmune serologies, and symptoms that are rapidly progressive. The Endocrine Society and ACR recommend that patients with secondary Raynaud's be evaluated for underlying connective tissue disease even if systemic symptoms are absent [3].

Thermography and laser Doppler flowmetry are research tools that quantify digital perfusion but are not routinely used in clinical practice. A complete blood count, ESR, CRP, and comprehensive metabolic panel round out the baseline evaluation to screen for associated conditions.

Patients taking beta-blockers, ergotamines, stimulants, or chemotherapy agents who develop new Raynaud's symptoms should have a medication reconciliation before any additional diagnostic workup is initiated, as drug withdrawal alone may resolve the condition [4].